

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#) | [Search Form](#) | [Posting Counts](#) | [Show \\$ Numbers](#) | [Edit \\$ Numbers](#) | [Preferences](#)**Search Results -**

Terms	Documents
118 and 113	0

Database:

US Patents Full-Text Database	▲
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Refine Search:**Clear****Search History****Today's Date: 10/1/2000**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,JPAB,EPAB,DWPI	l18 and l13	0	<u>L19</u>
USPT,JPAB,EPAB,DWPI	wolozin-b\$.in.	13	<u>L18</u>
USPT,JPAB,EPAB,DWPI	l16 and l13	2	<u>L17</u>
USPT,JPAB,EPAB,DWPI	yan-s\$.in.	151	<u>L16</u>
USPT,JPAB,EPAB,DWPI	yan.s\$.in.	0	<u>L15</u>
USPT,JPAB,EPAB,DWPI	l12 and l13	7	<u>L14</u>
USPT,JPAB,EPAB,DWPI	(advanced adj1 glycation adj1 end adj1 product\$1) or rage	2334	<u>L13</u>
USPT,JPAB,EPAB,DWPI	stern-d\$.in.	359	<u>L12</u>
USPT,JPAB,EPAB,DWPI	stern-d\$.in.	0	<u>L11</u>
USPT,JPAB,EPAB,DWPI	l8 or l9	1	<u>L10</u>
USPT	l7 and (advanced adj1 glycation adj1 end adj1 product\$1)	0	<u>L9</u>
USPT	l7 and rage	1	<u>L8</u>
USPT	presenilin\$ and amyloid\$	20	<u>L7</u>
USPT	l5 and amyloid\$	1	<u>L6</u>
USPT	l3 and rage	23	<u>L5</u>
USPT	l3 and (receptor adj3 advanced adj1 glycation adj1 end adj1 product)	1	<u>L4</u>
USPT	l1 or l2	14511	<u>L3</u>
USPT	((435/4 435/69.1 435/172.1 435/320.1 435/368 435/455)!.CCLS.)	12174	<u>L2</u>
USPT	((536/23.1 536/23.5)!.CCLS.)	6256	<u>L1</u>



Generate Collection

L14: Entry 2 of 7

File: EPAB

Jul 31, 1997

PUB-NO: WO009726913A1

DOCUMENT-IDENTIFIER: WO 9726913 A1

TITLE: A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID- beta PEPTIDE

PUBN-DATE: July 31, 1997

INVENTOR-INFORMATION:

NAME

COUNTRY

STERN, DAVID

N/A

SCHMIDT, ANN MARIE

N/A

YAN, SHI DU

N/A

ASSIGNEE-INFORMATION:

NAME

COUNTRY

UNIV COLUMBIA

US

APPL-NO: US09700857

APPL-DATE: January 21, 1997

PRIORITY-DATA: US59207096A (January 26, 1996)

INT-CL (IPC): A61K 39/395; A61K 38/00; C07K 16/00

EUR-CL (EPC): C07K014/705; C07K014/47, C07K016/28

ABSTRACT:

The present invention provides for a method for inhibiting interaction of an amyloid-beta peptide with a receptor for advanced glycation end product on the surface of a cell which comprises contacting the cell with an agent capable of inhibiting interaction of the amyloid- beta peptide with the receptor for advanced glycation end product, the agent being present in an amount effective to inhibit interaction of the amyloid- beta peptide with the receptor for advanced glycation end product on the surface of the cell. Another embodiment of this invention is a method for evaluating the ability of an agent to inhibit binding of an amyloid- beta peptide with a receptor for advanced glycation end product on the surface of a cell which includes: a) contacting the cell with the agent and amyloid- beta peptide; b) determining the amount of amyloid- beta peptide bound to the cell and c) comparing the amount of bound amyloid- beta peptide determined in step b) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit the binding of amyloid- beta peptide to the receptor for advanced glycation end product on the surface of the cell.